Skip to main content
SpringerLink
Log in

Complete prevention of the clinical expression of adjuvant-induced arthritis in rats by cyclosporin-A and lobenzarit: The regulation of lymph node cell populations and cytokine production

  • Original Research Papers
  • Published:
Inflammation Research Aims and scope Submit manuscript

Abstract

A single dose of either cyclosporin-A (CsA) or lobenzarit (CCA) given with an arthrogenic adjuvant completely prevented expression of experimental adjuvant arthritis in rats. The aim of this study was to understand how these drugs prevented the arthritis expression by studying the popliteal lymph nodes draining the arthritic joints at various times after adjuvant injection. Neither drug affected the proliferation in popliteal lymph nodes at the time arthritis was normally expressed, however, there was a marked change in the types of cells present. Immunofluorescence assays showed a reduction in the proportion of CD4+ cells, while the proportion of B-lymphocytes was almost doubled. This coincided with a marked elevation in the ability of these cells to produce interleukin (IL)-6. At the same time production of other cytokines (IL-2), tumour necrosis factor (TNF) and interferon (IFN)-γ) was not greatly affected. However, one day after adjuvant injection IL-2 and IFN-γ production was reduced. In vitro experiments showe that IL-6 production by lymphoid cells was relatively unaffected by CsA and CCA but IL-2, TNF and IFN-γ were suppressed by CsA. The results indicate that CsA and CCA may modify the response to the arthritic adjuvant by specifically inhibiting IL-2, TNF and IFN-γ production at the time of adjuvant injection. The lack of inhibition of IL-6 by these drugs reveals it may not play a key role in the initiation of this model of chronic inflammation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Elliott MJ, Maini RN, Feldmann M, Long-Fox A, Charles P, Katsikis P, et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor α. Arthr Rheum 1993;36:1681–90.

    Google Scholar 

  2. Haynes DR, Garrett IR, Vernon-Roberts B. Effect of gold salt treatment on receptor binding activity of monocytes and macrophages isolated from rats with adjuvant arthritis. Rheumatol Int 1988;8:159–64.

    Google Scholar 

  3. Connolly KM, Stecher VJ, Danis E, Purden DJ, LaBrie T. Alteration of interleukin-1 activity and the acute phase response in adjuvant arthritic rats treated with disease modifying drugs. Agents Actions 1988;25:94–105.

    Google Scholar 

  4. Dougados M, Torley H. Efficacy of cyclosporin A in rheumatoid arthritis: worldwide experience. Br J Rheumatol. 1993;(1 Suppl)32:57–9.

    Google Scholar 

  5. Sany J. Immunological treatment of rheumatoid arthritis. Clin Exp Rheumatol 1990;(5 Suppl)8:81–8.

    Google Scholar 

  6. Clerici M, Shearer GM. Differential sensitivity of human T helper cell pathways by in vitro exposure to cyclosporin A. J Immunol 1990;144:2480–5.

    Google Scholar 

  7. Katagiri K, Nakano T, Sugawara Y, Ichikawa Y, Yoshida T. CCA (disodium 4-chloro-2,2′-iminodibenzoate) inhibits the progression of human T cell proliferation triggered by PHA. Clin Immunol Immunopathol 1990;56:384–92.

    Google Scholar 

  8. Varey A, Champion BR, Cooke A, Cyclosporin affects the function of antigen-presenting cells. Immunol 1986;57;111–4.

    Google Scholar 

  9. Takeuchi T, Koide J, Hosono O, Takano M, Abe T. CCA [N-(2-carboxyphenyl)-4-chloroanthranilic acid sodium sal], a newly developed immunomodulating drug, suppresses T-cell activation by acting on macrophages. Inflammation 1989;13:124–35.

    Google Scholar 

  10. Klaus GGB. Cyclosporin-sensitive and cyclosporin-insensitive modes of B cell stimulation. Transplantation 1988;46:11S-4.

    Google Scholar 

  11. Hirohata S, Shinohara S, Inuoue T, Miyamoto T, Lipsky PE. Regulation of B cell function by lobenzarit, a novel disease-modifying antirheumatic drug. Arthr Rheum 1992;35:168–74.

    Google Scholar 

  12. Takeda Y, Urakawa K, Sakamoto A, Nakano T, Sugawara Y, Ohsugi Y, et al. Lobenzarit disodium (CCA) inhibits in vitro immunoglobulin production via direct interaction with B lymphocytes. Chem Pharm Bull Tokyo 1992;40:177–181.

    Google Scholar 

  13. Del-Pozo E, Graeber M, Elford P, Payne T. Regression of bone and cartilage loss in adjuvant arthritic rats after treatment with cyclosporin A. Arthr Rheum 1990;33:247–52.

    Google Scholar 

  14. Whitehouse MW, Rainsford KD, Taylor RM, Vernon-Roberts B. Zinc monoglycerate: A slow release source of zinc with antiarthritic activity in rats. Agents Actions 199031:47–58.

    Google Scholar 

  15. Imaizumi K, Hinoue H, Ueno M, Takata I, Sato T, Minato Y, et al. Pathological evaluation of anti-rheumatic drugs on type II collagen-induce arthritis in DBA/1J mouse. Jikken Dobutsu 1991;40:95–9.

    Google Scholar 

  16. Whitehouse MW, Vernon-Roberts B. Prevention of rat polyarthritis induced with mycobacterial or avridine adjuvants. XVIIth ILAR Congress of Rheumatology 1989;13.

  17. Haynes DR, Garrett IR, Whitehouse MW, Vernon-Roberts B. Do gold drugs inhibit interleukin-1? Evidence from an in vitro lymphocyte activating factor assay. J Rheumatol 1988;15:775–8.

    Google Scholar 

  18. Haynes DR, Whitehouse MW, Vernon-Roberts B. The prostaglandin analogue, Misoprostol regulates inflammatory cytokines and immune functions in vitro like the natural prostaglandins E2, E2 and E3. Immunol 1992;76:251–7.

    Google Scholar 

  19. Bazin H, Xhurdebise LM, Burtonboy G, LeBaq AM, De Clercq L, Cormont F. Rat monoclonal antibodies. i. rapid purification from in vitro culture supernatants. J Immunol Meth 1984;66:261–9.

    Google Scholar 

  20. Hunig T, Wallny H-J, Hartley JK, Lawetzky A, Tiefenthaler G. A monoclonal antibody to a constant determinant of the rat T cell antigen receptor that induces T cell activation: different reactivity with subsets of immature and mature T lymphocytes. J Exp Med 1989;169:73–86.

    Google Scholar 

  21. Fukumoto T, McMaster WR, Williams AF. Mouse monoclonal antibodies against rat major histocompatibility antigens. Two Ia antigens and class I antigens in rat thymus. Eur J Immunol 1982;12:237–43.

    Google Scholar 

  22. Dallman MJ, Mason DW, Webb M. The roles of host and donor cells in the rejection of skin allografts by T cell-deprived rats injected with syngenetic T cells. Eur J Immunol 1982;12:511–18.

    Google Scholar 

  23. Mason DW, Brideau RJ, McMaster WR, Webb M, White RAH, Williams AF. Monoclonal antibodies that define T-lymphocyte subsets in the rat. In: Kennett RH, McKearn TJ, Bechtol KB, editors. Monoclonal antibodies. London: Plenum Publishing Corp., 1980;251–301.

    Google Scholar 

  24. Gadd SJ, Ashman LK. Binding of mouse monoclonal antibodies to human leukemia cells via the Fc receptor: a possible source of ‘false positive’ reactions in specificity. Clin Exp Immunol 1983;54:811–8.

    Google Scholar 

  25. Snedecor GW, Cochran WG, editors. Statistical Methods. 8th ed. Ames, Iowa: Iowa State University Press, 1989.

    Google Scholar 

  26. Madhok R, Capell HA. Cyclosporin A in Rheumatoid Arthritis: Results at 30 months. Transplant Proc 1988;20(4 Suppl):248–52.

    Google Scholar 

  27. Cohen IR, Holoshitz J, Van Eden, Frenkel A. T lymphocyte clones illuminate pathogenesis and affect therapy of experimental arthritis. Arthr Rheum 1985;28:841–5.

    Google Scholar 

  28. Larsson P, Holmdahl R, Denker L, Klareskog L. In vivo treatment with W3/13 (anti-pan T) but not with OX8 (antisuppressor/cytotoxic T) monoclonal antibodies impedes the development of adjuvant arthritis in rats. Immunol 1985;56:383–91.

    Google Scholar 

  29. Hess AD, Tutschka PJ, Santos GW. Effect of cyclosporin A on human lymphocyte responses in vitro. III. CsA inhibits the production of T lymphocyte growth factors in secondary mixed lymphocyte responses but does not inhibit the response of primed lymphocytes to TCGF. J Immunol 1982;128:355–91.

    Google Scholar 

  30. Groeniwegen G, Buurman WS, Jeanhomme GMA, Van Der Linden CJ. Effect of cyclosporin on MHC class II antigen expression on arterial and venous endothelium in vitro. Transplantation 1985;40:21–5.

    Google Scholar 

  31. Kunkl A, Klauss GGB. Selective effects of cyclosporin A on functional B cell subsets. J Immunol 1980;125:2526–31.

    Google Scholar 

  32. White DJD, Plumb A, Clane RY. The immune status of transplantation recipients immunosuppressed with cyclosporin A Transplant Proc 1980;13:1666–8.

    Google Scholar 

  33. Van Den Broek MF, Van Den Langerit LG, Van Bruggen MC, Billingham MEJ, Van den Berg WB. Treatment of rats with monoclonal anti-CD4 induces long term resistance to streptococcal cell wall-induced arthritis. Eur J Immunol 1992;22:57–61.

    Google Scholar 

  34. Mosmann TR, Coffman RL. TH1 and TH2: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol 1989;7:145–73.

    Google Scholar 

  35. Andersson J, Nagy S, Groth C-G, Andersson U. Effects of FK 506 and cyclosporin A on cytokine production studies in vitro at a single-cell level. Immunol 1992;75:136–42.

    Google Scholar 

  36. Theisen-Popp P, Pape H, Müller-Peddinghaus R. Interleukin-6 in adjuvant arthritis of rats and its pharmacological modulation. Int J Immunopharmacol 1992;14:565–71.

    Google Scholar 

  37. Smith-Oliver T, Noel LS, Stimpson SS, Yarnall DP, Connolly KM. Elevated levels of TNF in the joints of adjuvant arthritic rats. Cytokine 1993;5:298–304.

    Google Scholar 

  38. Brauer R, Kette H, Henzgen S, Thoss K. The influence of cyclosporin A on cytokine levels in synovial fluid and serum in rats with antigen induced arthritis. Agents Actions 1994;41:96–8.

    Google Scholar 

  39. Weinblatt M, Helfgott S, Coblyn J, Spragg J, Uedelhoven WM, Tumel S, et al. The effects of cyclosporin A on eicosanoid excretion in patients with rheumatoid arthritis. Arthr Rheum 1991;34:481–5.

    Google Scholar 

  40. Hart PH, Whitty GA, Piccoli DS, Hamilton JA. Control by IFN-γ and PGE2 of TNFα and IL-1 production by human monocytes. Immunol 1989;66:374–83.

    Google Scholar 

  41. Reem GH, Cook LA, Vilcek J. Gamma interferon synthesis by human thymocytes and T lymphocytes inhibited by cyclosporin A. Science 1983;222:63–65.

    Google Scholar 

  42. Hirohata S. Regulation of in vitro anti-DNA antibody production by a novel disease modifying anti-rheumatic drug, Lobenzarit. Clin Exp Rheumatol 1992;10:357–63.

    Google Scholar 

  43. Okamoto M, Sasano M, Goto M, Nishioka K, Nakamura K, Yokohari R. Suppressive effect of anti-rheumatic drugs on interleukin-1 beta release from human peripheral blood monocytes. Int J Immunopharmacol 1991;13:39–43.

    Google Scholar 

  44. Kawakami A, Eguchi K, Ueki Y, Migita K, Ida H, Nakao H, et al. Effects of lobenzarit disodium on human endothelial cells. Lobenzarit disodium inhibits proliferative response, HLA-DR antigen expression, and T cell adherence toward endothelial cells. Arthr Rheum 1991;34:296–303.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pathology, University of Adelaide, 5005, Adelaide, SA, Australia

    D. R. Haynes & B. Vernon-Roberts

  2. Department of Microbiology and Immunology, University of Adelaide, 5005, Adelaide, SA, Australia

    G. Mayrhofer

  3. Institute of Immunology, University of Vienna, Borschkegasse 8a, A-1090, Vienna, Austria

    S. J. Gadd

  4. Department of Medicine, University of Queensland, Princess Alexandra Hospital, 4102, Wooloongabba, Qld., Australia

    M. W. Whitehouse

Authors
  1. D. R. Haynes
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S. J. Gadd
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. W. Whitehouse
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. G. Mayrhofer
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. B. Vernon-Roberts
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

accepted by R. O. Day

Rights and permissions

Reprints and permissions

About this article

Cite this article

Haynes, D.R., Gadd, S.J., Whitehouse, M.W. et al. Complete prevention of the clinical expression of adjuvant-induced arthritis in rats by cyclosporin-A and lobenzarit: The regulation of lymph node cell populations and cytokine production. Inflamm Res 45, 159–165 (1996). https://doi.org/10.1007/BF02285155

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02285155

Key words

Search

Navigation